Stock Market Update - August 27, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. CELU - Celularity Inc.
Price: $2.1 | Change: +138.53% ($1.2196)
CELU saw an incredible 138.53% gain recently! This significant jump came after Celularity Inc. announced a new U.S. manufacturing partnership on August 27, 2026.
The collaboration is with Singapore-based MuseCell Innovations Pte. Ltd., focusing on producing their Dezawa MuseCells and related advanced biological products at Celularity's facility in Florham Park, New Jersey. This strategic move is expected to bring in over $300 million in aggregate purchases for Celularity over the next five years.
What makes this particularly interesting is the anticipated creation of over 200 high-tech jobs at the Florham Park site, across areas like biomanufacturing and quality control. This expansion not only signifies a substantial revenue boost but also a significant growth in Celularity's operational capabilities in the biotechnology space.
2. PPCB - Propanc Biopharma, Inc.
Price: $2.23 | Change: +108.41% ($1.16)
PPCB recently soared with an impressive 108.41% gain, largely driven by compelling new preclinical data from Propanc Biopharma. The biopharmaceutical company announced strong findings for its lead drug candidate, PRP, in models of pancreatic ductal adenocarcinoma (PDAC), a particularly challenging cancer.
In lab studies, PRP achieved over 90% tumor growth inhibition and extended median overall survival by more than 2.5 times in advanced PDAC models. What's particularly noteworthy is PRP's unique mechanism; it works by promoting malignant cell differentiation and targeting cancer stem cells, rather than traditional cytotoxic methods. The data also highlighted a reduction in cancer spread and an improved response to standard chemotherapy.
These positive results bolster the company's plans to advance PRP to a Phase 1b human study, with a clinical trial application expected in late 2026. Adding to the intrigue, PRP already holds FDA Orphan Drug Designation for pancreatic cancer, and the company has initiated a share repurchase program, signaling management's confidence in the stock's underlying value.
3. LGPS - LogProstyle Inc.
Price: $1.52 | Change: +74.85% ($0.6507)
LGPS:AMEX saw a significant 74.85% gain around August 28, 2026. This surge followed LogProstyle Inc.'s announcement that it would acquire I-FLATZ Corporation, a real estate firm based in Osaka, Japan, along with its subsidiary.
This strategic move is designed to expand LogProstyle's successful real estate business beyond the greater Tokyo area and deeper into Japan's Kansai region. I-FLATZ brings expertise in new condominium sales, resale of renovated units, and real estate leasing, which is expected to perfectly complement LogProstyle's current operations in renovation, resale, and development.
What makes this acquisition particularly interesting is LogProstyle's plan to retain I-FLATZ's existing management team. This suggests a focus on smooth integration and leveraging current talent, aiming to maximize the benefits and operational harmony from this expansion into new markets.
4. VNRX - VolitionRX Ltd
Price: $0.501 | Change: +47.70% ($0.1618)
VNRX saw its stock jump by an impressive 47.70% recently, following a flurry of positive updates from VolitionRx Ltd. The biggest news came from a peer-reviewed paper in Critical Care Medicine, which validated their Nu.Q® NETs test as a strong predictor for severe sepsis outcomes. This scientific backing significantly boosts the potential for their technology in the massive $2.8 billion sepsis market.
Adding to the good news, the company reported robust financial performance with revenue soaring 112% in the first half of 2026 to $1.4 million. They also submitted a key manuscript for their Nu.Q® Vet test, designed to detect lymphoma in cats, which is expected to trigger a $5 million milestone payment.
What makes this particularly interesting is VolitionRx's active discussions with over a dozen diagnostic companies for licensing deals, suggesting broader adoption of their Nu.Q® technology could be on the horizon. The combination of clinical breakthroughs, financial growth, and promising commercial talks seems to be fueling investor optimism.
5. PONOR - Pono Capital Four, Inc. Rights
Price: $0.28 | Change: +29.81% ($0.0643)
PONOR (NASDAQ) recently surged by an impressive 29.81%. This significant rise follows the announcement of a definitive merger agreement between Pono Capital Four, a special purpose acquisition company (SPAC), and Blackstar Orbital Technologies Corporation.
Blackstar Orbital Technologies is an aerospace firm focused on developing reusable spacecraft and orbital transportation systems. The merger, announced on August 6, 2026, values Blackstar at a base of $380 million. Upon closing, the combined entity will be renamed Blackstar Orbital Corporation.
This business combination is expected to significantly enhance Blackstar Orbital's capabilities, particularly with its SpaceDrone™ platform, and facilitate global expansion. The goal is to improve access to space for both government and commercial sectors, marking an interesting development in the growing space technology market.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.